15 firms writing Biotech checks in Boston, led by Sofinnova Investments, Atlas Venture, Casdin Capital — ranked by verified deal count with the companies.
Biotech in Boston accounts for 34 tracked companies with verified cap-table data, 34 of which disclose round sizes totalling $7.7B. The median disclosed raise is $144M, and the largest is Kailera Therapeutics at $1.6B, ahead of Odyssey Therapeutics ($726M) and Astria Therapeutics ($700M).
The names that recur most often on these biotech cap tables are Alexandria Venture Investments (5 companies), Cormorant Asset Management (5 companies), Janus Henderson Investors (5 companies), Atlas Venture (4 companies), ARCH Venture Partners (4 companies), Sanofi Ventures (4 companies). By latest disclosed round, the market skews Series A (19), Series B (7), Series D (2), Growth (2).
Companies tracked: 34
Disclosed funding total: $7.7B across 34 companies
Median disclosed raise: $144M
Largest raise: Kailera Therapeutics — $1.6B
Stage mix: Series A 19 · Series B 7 · Series D 2 · Growth 2
